741 results about "Tumor tissue" patented technology

A neurosurgery system for probing brain tissue of a patient for tumorous tissue. The system including a suction tool, an excitation source, an optical instrument, and a controller. The suction tool including a suction cannula defining a lumen, an optical fiber configured to transmit fluorescence emitted by the brain tissue; and an indicator configured to selectively emit visible light. An excitation source is configured to emit an excitation light having a wavelength to induce the fluorescence in the tumorous tissue. The optical instrument is coupled to the optical fiber. The optical instrument configured to convert the fluorescence emitted by the brain tissue and transmitted by the optical and configured to determine that the brain tissue is tumorous based on the electrical signal and activate the indicator based on the determination.

Disclosed herein are methods and compositions for preventing or reducing adverse events associated with administration of a RAS(ON) inhibitors. Thus, disclosed are compositions and methods for treating or preventing RAS(ON) inhibitor therapy-associated rash or mucositis. The methods involve administering a compound that binds to cyclophilin A (CypA) to compete with a RAS(ON) inhibitor for CypA binding, thereby reducing tri-complex formation in non-tumor tissues. These approaches may improve the tolerability of RAS(ON) inhibitor therapies without compromising efficacy.

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The invention provides application of lactic acid modified histone H3 in preparation of drugs and / or diagnostic kits for preventing and / or treating pancreatic ductal adenocarcinoma, and belongs to the technical field of disease diagnosis and / or treatment. The invention provides application of a lactic acid modified histone H3 as a target spot in preparation of a pancreatic ductal adenocarcinoma diagnostic kit or a medicine for preventing and / or treating pancreatic ductal adenocarcinoma. The site of lactic acid modification is 23-site lysine. The expression of H3K23la detected in clinical sample tissues in pancreatic ductal adenocarcinoma tumor tissues is obviously higher than that in para-carcinoma normal tissues, overexpression and non-expression of H3K23la in cells are regulated and controlled through in-vitro experiments in combination with overexpression and knock-down technologies, and results show that proliferation, invasion and migration capacities of pancreatic ductal adenocarcinoma cells are remarkably inhibited, so that the pancreatic ductal adenocarcinoma cells are remarkably inhibited. Therefore, the H3K23la can be used as a target spot for diagnosis and treatment of the pancreatic duct adenocarcinoma, and has wide application in diagnosis or treatment of the pancreatic duct adenocarcinoma.

The invention discloses a multi-modal tumor identification method based on a frequency domain attention mechanism. The method comprises the following steps: S1, acquiring multi-frequency bioelectrical impedance signals of tumor tissues and normal tissues and corresponding medical tumor pathological images; s2, extracting a frequency-time feature of the electrical impedance signal and a spatial feature of the pathological image through a multi-modal feature coding module, and generating a multi-modal fusion feature; s3, converting the multi-modal fusion features into frequency domain representation, performing weighted enhancement on the multi-modal fusion features through a frequency domain attention module, and outputting the features; and S4, fusing the features output by the frequency domain attention module and the superficial layer features in the coding stage through jump connection to obtain enhanced features, inputting the enhanced features into a decoding network, and outputting a tumor classification result. According to the method, the bioelectrical impedance signal and the multi-modal information of the pathological image are fused, and a frequency domain attention mechanism is introduced to effectively improve the expression ability of key frequency characteristics.

The invention relates to the field of biomedical treatment, and particularly discloses application of CD146 in diagnosis and treatment of rhabdomyosarcoma, and the CD146 is specifically and highly expressed in tumor tissues of the rhabdomyosarcoma. The invention provides application of a biomarker for diagnosing rhabdomyosarcoma or / and a detection reagent thereof in preparation of a product for diagnosing rhabdomyosarcoma. Meanwhile, experiments prove that the CD146-targeted chimeric antigen receptor T cell has a relatively strong tumor cell killing effect and can effectively remove CD146 positive tumor cells. The CD146 biomarker provided by the invention provides a new target and theoretical basis for early diagnosis and individualized treatment of rhabdomyosarcoma, and has important clinical application value.

The invention discloses a high-specificity minimal residual disease (MRD) monitoring method and system based on circulating tumor DNA (ctDNA). The method comprises the following steps: receiving tumor tissue sequencing data of an UTUC patient, and generating a double-Panel target list containing personalized and fixed Panel; respectively extracting plasma cfDNA and leukocyte gDNA; performing vacuum concentration, hybrid capture and sequencing on the cfDNA library by using the double Panel lists, and performing deep sequencing on the leukocyte gDNA; constructing an individualized clonal hematopoietic mutation filtering database; actively filtering and rejecting clonal hematopoietic background mutation by utilizing a filtering database; and calculating an MRD load score based on the filtered tumor-derived mutation and outputting a report. The system comprises corresponding modules which are used for automatically executing the process. According to the invention, through cooperation of four major technologies of double-Panel design, process optimization, UMI error correction and active clonal hematopoietic filtration, MRD monitoring with extremely high sensitivity and specificity on UTUC is realized, false positive is significantly reduced, and the kit has drug resistance early warning potential.

The invention discloses a manganese-enriched albumin boron-containing nano preparation as well as a preparation method and application thereof, and belongs to the field of medicines and nano biological materials. According to the manganese-enriched albumin boron-containing nano preparation, albumin serves as a core carrier, phenylboronic acid derivatives are loaded through covalent or electrostatic interaction, then a manganese oxide layer is deposited on the surface in situ, and the prepared manganese-enriched albumin boron-containing nano preparation can remarkably increase the boron accumulation amount in tumor tissue; local and systemic immune response of tumors is promoted through the immune activation effect of manganese ions, so that the treatment effect of boron neutron capture therapy (BNCT) is remarkably improved. According to the invention, a phenylboronic acid derivative with tumor targeting is compounded with albumin, and manganese oxide is deposited in situ on the surface of the phenylboronic acid derivative, so that a multifunctional nano preparation with high boron delivery efficiency, immunological enhancement and magnetic resonance imaging functions is formed.

The invention belongs to the technical field of biological medicines, and particularly discloses a bionic nano-vesicle for regulating and controlling neutrophil phenotype in combination with ultrasound, and a preparation method and application of the bionic nano-vesicle. The bionic nano-vesicle provided by the invention can be broken under the action of high-concentration glutathione existing in a tumor tissue microenvironment to release the sound-sensitive agent and functional siRNA, and under the action of US irradiation, the sound-sensitive agent is activated to generate a large amount of ROS, promote tumor cell DNA breakage, generate a large amount of double-stranded DNA, activate APC and promote IFN-beta release, so that the tumor tissue microenvironment is inhibited. The released functional siRNA can promote the N2-type neutrophile granulocyte to become N1-type neutrophile granulocyte, and the released functional siRNA can prevent the N1-type neutrophile granulocyte from being reversed to the N2-type neutrophile granulocyte again, so that the regulation and control on the phenotype of the neutrophile granulocyte are realized; under catalysis of CAT rich in the thylakoid membrane, H2O2 overexpressed by tumor tissue is decomposed into oxygen, the tumor hypoxia microenvironment can be relieved, and the tumor treatment effect can be improved.

The invention relates to the field of biology, and provides a human immortalized pancreatic cancer fibroblast as well as a preparation method and application thereof.The human immortalized pancreatic cancer fibroblast comprises three cell strains which are all primary fibroblast cells extracted from tumor tissues of pancreatic ductal adenocarcinoma patients, the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are classified and named as the human pancreatic cancer fibroblast cell strain CAFPC-2209131, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 respectively, the human pancreatic cancer fibroblast cell strain CAFPC-2209132 and the human pancreatic cancer fibroblast cell strain CAFPC-2303221 are all Cell STR identification and immunofluorescence detection prove that the cell strain is a fibroblast cell strain. After the tumor-associated fibroblast and pancreatic cancer cells are co-cultured, the proliferation ability of the tumor cells is obviously enhanced, and the sensitivity of the tumor cells to a chemotherapeutic drug gemcitabine is reduced. A new thought is provided for diagnosis and treatment of pancreatic cancer, and based on the pancreatic cancer in-vitro co-culture model established in vitro, the application has important significance for researching the effect and related mechanisms of fibroblasts in the pancreatic cancer tumor microenvironment.

The invention discloses a multifunctional hydrogel patch and a preparation method and application thereof.The biological patch comprises decellularized freeze-dried tumor tissue (dFCT) and a hydrogel layer loaded with hair melanin nanoparticles (HNPs), the dFCT is obtained by decellularizing and freeze-drying the tumor tissue, and rich natural extracellular matrix components are reserved; hNPs is extracted from hair and has excellent active oxygen scavenging capacity and photothermal conversion performance; it is preferable that the hydrogel layer is a methacrylated gelatin (GelMA). The patch disclosed by the invention shows a remarkable cell viability promoting effect and antibacterial ability in vitro, and can accelerate wound healing by reducing oxidative stress, inhibiting inflammatory response and promoting angiogenesis in vivo. The patch is simple and convenient in preparation process and natural in component source, has multiple functions of resisting bacteria, resisting oxidation, promoting tissue regeneration and the like, and is suitable for wound repair treatment.

The invention relates to the technical field of compound preparation and medicine, in particular to a boron atom-labeled compound for targeting fibroblast activating protein as well as a preparation method and application of the boron atom-labeled compound. The preparation method comprises the following steps: carrying out acid amine condensation on (4-(((2, 5-dioxopyrrolidine-1-yl) oxy) carbonyl) phenyl) boric acid and an FAP targeting ligand to obtain a boron atom-labeled compound targeting the fibroblast activating protein; and the FAP targeting ligand is FAPI-46 or FAP-2286 (Fibroblast Amplified Polymorphism). The compound is easy to prepare, high in purity and good in stability, the content of boron atoms in tumor tissue can be greatly increased, and a treatment basis is provided for boron neutron capture therapy.

The invention discloses a modular tumor microenvironment response polypeptide and a preparation method and application thereof. The modular tumor microenvironment response polypeptide is composed of the following functional modules: a targeting and chemotactic module used for targeting tumor cell surface p32 protein and tumor lymphatic vessels and promoting tumor tissue penetration and enrichment; the microenvironment double-response module is used for being cut by MMP-2 / 9 enzyme and broken by high-concentration glutathione GSH in a tumor microenvironment to trigger self-assembly; the self-assembly driving module is used for exposing after the microenvironment responds to activation and driving short peptides to be self-assembled to form a nano structure; a killing module: a pro-apoptotic peptide PAD used for targeting a mitochondrial membrane and inducing tumor cell apoptosis; and the stability optimization module is used for enhancing the degradation resistance of the oligopeptide. By integrating targeted delivery, enzyme digestion response, acid-sensitive release and stabilizing structures, the problems of insufficient targeting property, inaccurate release, poor stability, diagnosis-treatment splitting and the like of the anti-tumor drug and the developing agent are solved.

The invention belongs to the technical field of biological medicine, and particularly discloses nano composite particles based on a metal organic framework and a preparation method and application of the nano composite particles. The nano-composite particles are constructed through electron adsorption and coordination based on a nano-scale metal organic framework, and under the acidic microenvironment and ultrasonic irradiation of tumors, the nano-composite particles can be decomposed and released in a responsive manner, play a role of a sound-sensitive agent, generate a large amount of active oxygen and induce tumor cells to generate immunogenic death, so that the tumor cell immunogenicity is improved, and the tumor cell immunogenicity is improved. Further, more cytotoxic T lymphocytes are promoted to infiltrate a tumor microenvironment, T cell mediated anti-tumor immune response is recovered, and tumor metastasis is effectively prevented. The carrier metal organic framework ZIF8 of the nano-composite particles can serve as a sound-sensitive agent to generate active oxygen, the function of ultrasonic imaging of tumor tissue can be achieved, the effect of diagnosis is achieved while treatment is conducted, tumor diagnosis and treatment monitoring can be achieved at the same time through one-time drug administration, and a new strategy is provided for precise medical treatment.

The present application relates to a kind of pH / H2O2 dual-response drug-loaded hydrogel and its preparation method and application, by ε-polylysine derivative as antitumor active ingredient, with oxidized dextran through Schiff base reaction crosslinking rapid gelation. While using 2-formylphenyl boronic acid covalently package CD73 small molecule inhibitor APCP. ε-polylysine derivative has oncolytic activity, can induce ICD and promote the infiltration of immune cells in tumor cells. CD73 small molecule inhibitor APCP can block extracellular CD39-CD73-adenosine pathway, reduce the level of immunosuppressive metabolite adenosine in tumor tissue, so as to activate the infiltrated immune cells, restore its anti-tumor function. The hydrogel of ε-polylysine derivative and APCP co-delivery synergistically inhibits the effect of tumor growth, and its curative effect is greater than the treatment effect of single drug, and is superior to positive control drug oxaliplatin (OXA). The pH / H2O2 dual-response hydrogel is rapidly gelled, and has good biological safety under mild reaction conditions.

The invention belongs to the technical field of biological medicine, and particularly relates to a culture medium and method for constructing a liver cancer or bile duct cancer explant and application. According to the culture medium and the method for constructing the liver cancer or cholangiocarcinoma explant, tumor tissues cut by a liver cancer patient through an operation are utilized, an optimized explant culture medium is utilized for multiplication culture, and a liver cancer explant model with high activity and a complete structure can be constructed through construction of an explant culture method; the method can be used for screening and guiding drugs.

The invention relates to the technical field of tumor marker detection, in particular to a breast cancer lung metastasis related biomarker screening system which comprises a differential genetic factor mining module, a function association module, a verification screening module, an interference elimination module and an optimization integration module. According to the method, the candidate genetic factors highly associated with lung metastasis are extracted, and the expression fluctuation characteristics are combined to carry out difference analysis, so that the preliminary screening accuracy is improved, pathological information and pathway annotation are integrated to construct an action network, pathway weights are analyzed, and functional expressions of the candidate factors are quantitatively evaluated; an independent sample is called to verify transcription consistency and clinical relevance, interference factors with poor repeatability are eliminated, non-tumor tissue high-expression interference items are rejected in combination with background transcription characteristics, the specificity and adaptability of screening results are improved, and finally a marker set with metastasis mechanism indicating significance and prognosis prediction value is formed through comprehensive evaluation. And clinical transformation support is provided for identification of lung metastasis of breast cancer.

The invention relates to the technical field of medical equipment, in particular to a tumor puncture sampling device which comprises a body, a cannula, a needle core, a limiting mechanism, an excitation mechanism and a plugging mechanism. By changing the shape of the front end of the needle core, the end face of the front end of the sampling groove is flush with the end face of the front end of the needle core, so that the tumor tissue is directly cut in the process that the needle core pierces the tumor tissue, and the problem that in the prior art, a puncture needle with the front end being a solid cylinder pushes away the tumor tissue is solved; when the cannula is pierced, a tissue sample and tumor tissue around the tissue sample are cut off, and when the cannula moves by a preset distance, the plugging mechanism cuts off the front end of the tissue in the sampling groove, so that the sample is completely separated from the tumor tissue, and the plugging assembly plugs a gap between the needle core and the cannula, so that the tissue sample is prevented from being separated from the sampling groove. The problem that in the prior art, when a puncture sampling needle conducts puncture sampling, the needle core pushes away tumor tissue, and consequently the tissue sampling amount is insufficient is solved.

A method for treating tumors using a combination of an oncolytic virus vaccine and immune cells. The method specifically includes the following step: treating the tumors by using a combination of the immune cells and the oncolytic virus vaccine; the oncolytic virus vaccine includes a recombinant oncolytic virus expressing a tumor antigen and is used for targeting the tumor cells; the immune cells express a chimeric antigen receptor paired with the tumor antigen, and are used for killing or destroying the tumor cells targeted; the recombinant oncolytic virus includes an M protein, G protein, N protein, P protein and L protein subjected to site-directed mutagenesis. The tumor antigen expressed by the oncolytic virus vaccine can guide the immune cells to reach the target tumor tissue center, achieving a curative effect where 1+1 is greater than 2, with a tumor cell killing rate being up to 100% at most.

The invention discloses a tissue dissociation liquid, a tissue dissociation method and application thereof, and relates to the technical field of cell biology. In a DMEM / F12 culture medium, the tissue dissociation liquid only contains the following raw materials in concentration: 0.5 to 3 mg / mL of type II collagenase, 0.5 to 2 mg / mL of type IV collagenase, 0.5 to 2 mg / mL of hyaluronidase, 10 to 18 [mu] M of Y27632 and 80 to 150 [mu] g / mL of primocin. The tissue dissociation liquid provided by the invention can dissociate normal tissues or tumor tissues into single cells or cell clusters, the single cells obtained by the digestion method are high in proliferation rate and easy to successfully culture, and the tissue dissociation liquid has the technical advantages that the cell yield and survival rate are maintained at a relatively high level. Therefore, the tissue dissociation liquid provided by the invention has good application prospects in tumor tissue dissociation, cell line construction and organoid model construction.

The invention discloses a bioelectrical impedance tumor identification method based on multi-modal fusion. The method comprises the following steps: S1, acquiring electrical impedance signal data and tissue slice image data of a tumor sample; the tissue slice image data are pathological slice images corresponding to tumor tissues; s2, inputting the electrical impedance signal data and the tissue slice image data into a multi-modal feature coding module for asymmetric feature coding; s3, performing splicing and weighted fusion on the global semantic feature vector and the image semantic feature vector to form a multi-modal feature vector; and S4, inputting the multi-modal feature vector into a decoding network for classification prediction, and outputting a tumor identification result. According to the method, an asymmetric coding structure and a weighted fusion mechanism are constructed by fusing the electric signal modality and the image modality, so that the utilization efficiency and the feature discrimination capability of multi-modal information can be effectively improved, and the accuracy and the reliability of tumor recognition are remarkably improved.

The invention discloses a two-stage brain glioma segmentation system based on an improved U-Net model, and belongs to the field of medical image segmentation. According to the method, the problems of low precision, low efficiency and poor generalization ability of the existing segmentation technology are solved. In a tumor tissue detection stage, the lightweight neural network is utilized to realize preliminary identification of a brain glioma region, and the calculation range of subsequent fine segmentation is effectively reduced, so that the model can perform reasoning at relatively low resource and time cost, and the segmentation efficiency is improved. By adopting the multi-scale feature residual module, the problem of gradient disappearance caused by network deepening can be relieved, information can be propagated in a deeper level in the network, and extra parameter and calculation complexity overhead cannot be brought. Meanwhile, jump connection is changed into a multi-scale jump connection structure, the problem that a decoder network can only receive same-scale feature information is solved, and the tumor segmentation precision is remarkably improved. The method can be applied to medical image segmentation.

The invention relates to the technical field of biomedical engineering and drug delivery, and particularly discloses a novel targeted drug delivery system based on rose fruit extracellular vesicles, which comprises the following steps: preparing rose fruit source extracellular vesicles; preparing a medicine carrying vesicle; preparing targeted modified drug-loaded vesicles; according to the application disclosed by the invention, a stem related pathway is specifically down-regulated through the components of the rose fruits, and meanwhile, conventional tumor cells are killed by using adriamycin, so that a complementary treatment mechanism is formed, and the tumor recurrence risk is fundamentally reduced. The phenylboronic acid group of DSPE-PEG-PBA is used for specifically recognizing sialic acid over-expressed on the surface of a tumor cell, so that the enrichment of the medicine in tumor tissues is remarkably improved, and meanwhile, the distribution of normal tissues is reduced. By means of the natural biocompatibility and low immunogenicity of the RHNVs and in combination with the long circulation characteristic of a PEG chain, the delivery efficiency is guaranteed, the systemic toxicity is reduced to the maximum extent, and particularly the cardiotoxicity and myelosuppression of adriamycin are relieved.

The invention belongs to the technical field of biological pharmacy, and relates to a bifunctional fusion protein targeting PD-1 / PD-L1 and IL-33 as well as a construction method and application of the bifunctional fusion protein. The bifunctional fusion protein comprises a PD-1 / PD-L1 antibody and a targeted IL-33 functional fragment, T cells are activated by blocking a PD-1 / PD-L1 signal to kill tumor cells, meanwhile, the level of IL-33 in tumor tissue is reduced, and the activity of IL-33 is inhibited. Researches show that the bifunctional fusion protein can increase infiltration of functional T cells, enhance T cell response and remodel a tumor microenvironment so as to generate an anti-tumor effect superior to that of combined treatment, and has a very good application prospect.

The invention discloses a preparation method and application of a peptide specific quality nanoprobe. The nanoprobe is prepared by uniformly mixing mass tag molecules, functional polypeptide and a chloroauric acid solution and adding a sodium hydroxide solution through a simple one-pot method. The synthesized mass nanoprobe is specifically recognized and combined with target protein on cells or tissues through a peptide chain, and mass-to-charge ratio signals of mass tag molecules corresponding to different nanoprobes are detected through laser desorption ionization-time-of-flight mass spectrometry (LDI-TOFMS) ionization; the mass spectrum imaging analysis on the relative expression quantity of various proteins on different types of cancer cells and tumor tissue slices is realized. The probe has the characteristics of simple preparation, specific recognition, low background, high resolution and the like, and is easy to popularize to the detection of various proteins on the surfaces of other biological samples.

The present invention relates to a method for predicting a solid tumor immune cell therapy treatment response. The method comprises acquiring a tumor tissue section from a patient, and detecting the presence, number, proportion or density of one or more cell types in the tumor tissue section. A solid tumor immune cell therapy response is predicted by determining cell markers, such as α-SMA, CD3, CD4 or CD8, associated with the cell types. In addition, the present invention also relates to a kit used for predicting a solid tumor treatment response, including a reagent which detects expression levels of one or more cell types and cell markers in tumor tissue sections, and software and / or a user manual used for analyzing detection results. The method and kit provide an effective tool for clinical treatment, so as to optimize dosages and clinical regimens of immune cell therapy, thereby improving treatment response rates.

The invention discloses a human-derived hysteromyoma targeting peptide and application thereof, the sequence of the targeting peptide is selected from SEQ ID NO: 1 to SEQ ID NO: 5, and the SEQ ID NO: 1 (VN12) is the most preferable. The fusion protein is obtained by screening through a phage display technology, and has high hysteromyoma targeting specificity and low immunogenicity. The targeting peptide can be coupled with nuclide or fluorescent dye, and is used for accurate PET imaging, fluorescent diagnosis and intraoperative navigation of hysteromyoma. Experiments prove that the molecular marker is specifically enriched in tumor tissues (the tumor / muscle ratio is 60), the biological safety is good, the problems of insufficient diagnosis sensitivity and large treatment wound in the prior art are solved, and the molecular marker has a great application prospect in diagnosis and treatment of hysteromyoma.

According to the invention, IN10018 and a macromolecular drug are combined to treat tumors, and the macromolecular drug is a monoclonal antibody, a bispecific antibody or an antibody conjugate.

The invention discloses a method for accurately identifying benign and malignant cells based on multi-dimensional characteristics of a single cell transcriptome, and belongs to the technical fields of bioinformatics, tumor molecular biology and cell identification. On the basis of single cell transcriptome sequencing data of tumor tissues and para-carcinoma tissues, three types of information including copy number variation, allele specific copy number variation and tumor-related transcriptional characteristics are synthesized, and final benign and malignant identification is performed on each EpCAM positive epithelial cell through a multi-evidence voting strategy. The method disclosed by the invention has relatively high stability and accuracy in a multi-patient, multi-sample and early tumor scene, particularly improves the recognition capability of early lesion and malignant cells in benign and malignant boundary transition state cells, and provides a reliable technical means for precise diagnosis and individualized treatment of tumors.

The invention discloses an esophageal cancer targeting nano-tablet based on a traditional Chinese medicine composition and a preparation method of the esophageal cancer targeting nano-tablet. The targeted nano tablet is prepared from the following refined extracts: a rhizoma paridis total saponin extract, a pseudobulbus cremastrae seu pleiones colchicine derivative extract, a panax notoginseng total saponin extract, a carthamin yellow extract, a thunberg fritillary bulb total alkaloid extract, frankincense-myrrh compound volatile oil, a resin extract and an astragaloside IV extract. The nano-carrier comprises a nano-carrier, a seaweed-laminarin composite extract, a processed rhizoma pinelliae total alkaloid extract and costus root volatile oil, and the costus root volatile oil serves as one of targeting ligands to be used for modifying the nano-carrier. The targeting property is strong: the dual-targeting ligand (costunolide-TOPK affinity peptide) on the surface of the nano-carrier can actively recognize and combine with a specific receptor of esophageal cancer cells, and meanwhile, due to the size (about 100-200 nanometers) of the carrier, the carrier is easy to enrich in tumor tissues through enhanced permeation and retention (EPR) effect, so that the modernization upgrading of the idea of'channel guiding medicine 'is realized.